Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

M1 Kliniken focuses on beauty after pharma sale and shows rising profitability

M1 Kliniken is concentrating fully on the profitable beauty segment after selling its pharma business, which grew by 11% in H1 to €56.9m. Segment EBIT rose 23.8% to €18.6m and the margin climbed to 32.7%; management targets 2029 revenue of €200–300m and an EBIT margin of at least 20%. With a major shareholder (MPH Health Care) holding over 66% and low free float, M1 Kliniken is seen as an attractive takeover or going-private candidate; a price target of €26.50 (about 31% upside) is cited. » Mere på finanzen.net
M1 Kliniken posts double-digit revenue and margin growth in beauty business

Adjusted figures show M1 Kliniken’s core business increased revenue in H1 2026 by 11% to €56.9m and improved EBIT by almost 24% to €18.6m; in Q2 revenue growth accelerated to around 16%. The prior sharp decline in group metrics resulted from the deconsolidation and sale of wholesale subsidiary Haemato Pharm. Management confirms a mid-term target of €200–300m revenue by 2029 with an EBIT margin of at least 20% (H1 margin: >32%). Analysts raised the price target, leaving upside of almost 50%; the P/E for 2026 is expected to be below 14. » Mere på finanzen.net
M1 Kliniken impresses with robust growth and a strong dividend increase

M1 Kliniken's stock has risen in recent months to close to its all-time high. The Düsseldorf-based company reports robust growth and surprised with a significantly increased dividend. If the ambitious forecasts are met, the authors see further upside potential for the share price. » Mere på finanzen.net
M1 Kliniken boosts revenue, sharply raises dividend and confirms ambitious guidance

M1 Kliniken reports for 2025 a revenue increase of 7.4% to €364.3m and EBIT growth of 29.2% to €34.6m; the beauty clinics recorded revenue growth of 11.2% and an EBIT gain of 41.5%. The dividend is to rise from €0.50 to €1.20 per share, equivalent to a yield of more than 6%. Management reaffirms the mid‑term guidance of €200–300m in revenue and a sustainable EBIT margin of 20% by 2029; acquisitions are not excluded as a growth driver. A reduced share count due to buybacks and a cash reserve of more than €30m support further upside potential for the stock. » Mere på finanzen.net
M1 Kliniken approves 2025 financial statements and proposes dividend of EUR 1.20 per share

The supervisory board of M1 Kliniken has approved the annual and consolidated financial statements for 2025 submitted by the management board. The supervisory board and management board propose a dividend of EUR 1.20 per dividend-entitled share to the general meeting. The 2025 annual report is expected to be published on 20 May 2026. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har M1 Kliniken allerede udloddet 1,20 € i udbytte. Den seneste udlodning fandt sted i juli.

Virksomhedstal

I det seneste kvartal havde M1 Kliniken en omsætning på 76,6 mio. € og et nettoresultat på 9,72 mio. €

(EUR)	juni 2026	YoY
Omsætning	76,6 mio.	-
Bruttofortjeneste	23,6 mio.	-
Nettoresultat	9,72 mio.	-
EBITDA	17,68 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	345,5 mio. €
Antal aktier	18,56 mio.
Højeste/laveste i 52 uger	21,70 € - 13,62 €
Udbytteafkast	6,19 %
Udbytte TTM	1,20 €
Beta	0,99
P/E (PE Ratio)	17,08
PEG (PEG Ratio)	1,26
K/I (PB Ratio)	2,80
P/S (PS Ratio)	1,34

Virksomhedsprofil

M1 Kliniken AG driver sammen med sine datterselskaber medicinske centre for æstetisk og plastikkirurgi i Tyskland, Østrig, Holland, Schweiz, Storbritannien, Kroatien og Australien. Virksomheden opererer i to segmenter, Beauty og Trade. Den udvikler og markedsfører farmaceutiske, medicinske og medicinteknologiske produkter til æstetisk medicin og kosmetisk dermatologi, og handler desuden med farmaceutiske produkter, biosimilars og andre medicinske produkter og udstyr inden for onkologi, HIV, reumatisme, neurologi, kardiovaskulære sygdomme og narkotika. Virksomheden beskæftiger sig også med køb, forvaltning og salg af fast ejendom, primært i sundhedssektoren. Den tilbyder sine produkter til læger, apoteker og grossister under mærket M1 Select. Virksomheden driver et netværk af ambulante speciallægecentre samt et specialiseret kirurgisk klinikcenter og 46 speciallægecentre under mærket M1 Med Beauty. M1 Kliniken AG blev grundlagt i 2007 og har hjemsted i Berlin, Tyskland. M1 Kliniken AG er datterselskab af MPH Health Care AG.

Navn	M1 Kliniken
CEO	Attila Strauss
Hjemsted	Berlin, be Tyskland
Websted	m1-kliniken.de
Sektor	Sundhed
Branche	Sundhedsudbydere og -tjenester
Børsnotering	14.09.2015
Medarbejdere	280